{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:52Z","timestamp":1792239052300,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770132"],"award-info":[{"award-number":["81770132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873434"],"award-info":[{"award-number":["81873434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chimeric antigen receptor\u2010modified T\u2010cell (CAR\u2010T) therapy is effective and safe for patients with relapsed\/refractory B\u2010cell acute lymphoblastic leukemia (r\/r B\u2010ALL), but its value has been limited in terms of long\u2010term leukemia\u2010free survival. New strategies that can help CAR\u2010T therapy achieve lasting effect are urgently warranted. This non\u2010randomized interventional pragmatic clinical trial had a particular aim. It explored whether consolidative allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT) could improve the long\u2010term prognosis of the minimal residual disease\u2010negative complete remission (MRD\n                    <jats:sup>\u2212<\/jats:sup>\n                    CR) patients after CAR\u2010T therapy. In the first stage, 58 r\/r B\u2010ALL patients received split doses of CAR\u2010T cells after lymphodepleting chemotherapy, and 51 (87.9%) achieved CR. In the second stage, 21\/47 MRD\n                    <jats:sup>\u2212<\/jats:sup>\n                    CR patients without previous allo\u2010HSCT and contraindications or other restrictions, on their own accord, received consolidative allo\u2010HSCT within three months after CAR\u2010T therapy. There was no difference in overall survival (OS) between the MRD\n                    <jats:sup>\u2212<\/jats:sup>\n                    CR patients who received allo\u2010HSCT and those who did not. However, event\u2010free survival (EFS) and relapse\u2010free survival (RFS) were significantly prolonged by allo\u2010HSCT in the subgroups. This was with either high (\u22655%) pre\u2010infusion bone marrow MRD assessed by flow cytometry (BM\u2010FCM\u2010MRD) or poor prognostic markers (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u2009.05). However, no difference was found in EFS and RFS for patients with pre\u2010infusion BM\u2010FCM\u2010MRD\u2009&lt;5% and without poor prognostic markers (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&gt;\u2009.05). To conclude, CAR\u2010T therapy bridging to allo\u2010HSCT is a safe and effective therapeutic strategy for r\/r B\u2010ALL patients, and may prolong their EFS and RFS, especially when they have high pre\u2010infusion BM\u2010FCM\u2010MRD or poor prognostic markers.\n                  <\/jats:p>","DOI":"10.1002\/ajh.25582","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T02:53:48Z","timestamp":1563504828000},"page":"1113-1122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Anti\u2010CD19 chimeric antigen receptor\u2010modified T\u2010cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B\u2010cell acute lymphoblastic leukemia: An open\u2010label pragmatic clinical trial"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9973-4335","authenticated-orcid":false,"given":"Huiwen","family":"Jiang","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics School of Public Health, Tongji Medical College, Huazhong University of Science and Technology  Wuhan 430030 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Department of Pediatrics Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Ai","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhe","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runming","family":"Jin","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Department of Pediatrics Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dong","sequence":"additional","affiliation":[{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan 430022 China."},{"name":"Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease  Wuhan 430022 China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70580-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12243"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5RU0817-315R"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0593-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14680"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03685-z"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5037-7"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402552"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12639"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12602"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4258"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"issue":"6","key":"e_1_2_8_36_1","first-page":"957","article-title":"Incidence and clinical outcome of children with BCR\/ABL\u2010positive acute lymphoblastic leukemia (ALL). A prospective RT\u2010PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL\u2010BFM\u201090 and CoALL\u201005\u201092","volume":"10","author":"Schlieben S","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-015-0149-0"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.161"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.152"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04113.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0246-1"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"issue":"10","key":"e_1_2_8_46_1","first-page":"802","article-title":"CD19\u2010targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B\u2010cell acute lymphoblastic leukemia","volume":"14","author":"Davila ML","year":"2016","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T22:39:42Z","timestamp":1694126382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1002\/ajh.25582"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25582","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"2019-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}